Zauli Giorgio, Sancilio Silvia, Cataldi Amelia, Sabatini Nadia, Bosco Domenico, Di Pietro Roberta
Dipartimento di Morfologia Umana Normale, Università di Trieste, Via Manzoni, Trieste, Italy.
J Cell Physiol. 2005 Mar;202(3):900-11. doi: 10.1002/jcp.20202.
The aim of this work was to evaluate the involvement of survival pathways in the response of Jurkat T leukaemic cells sensitive to the cytotoxic action of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/Apo2L. Jurkat T cells express TRAIL-R2/DR5 and TRAIL-R4/DcR2 receptors and start to die by apoptosis early (3 h) upon TRAIL administration reaching a dose-dependent increase in the percentage of dead cells within 48 h (up to 85-90%). This increase in cell death is accompanied by a dose-dependent significant (P < 0.05) increase in the G0/G1 phase of the cell cycle and reverted by the treatment with a broad inhibitor of caspases, z-VAD-fmk. Co-treatment of the cells with inhibitors of PI-3 kinase (LY294002) and nuclear factor kappa B (NF-kappaB) (SN50) pathways leads to an earlier significantly increased cytotoxicity, respectively in the form of apoptosis and necrosis. Consistently with the data obtained with the pharmacological inhibitors, the activation and nuclear translocation of both PI-3K and NF-kappaB were observed. In summary, our results provide evidence that even in sensitive neoplastic cells TRAIL paradoxically activates pro-survival pathways, which protect against TRAIL-mediated death since their inhibition leads to an earlier and increased cytotoxicity.
这项工作的目的是评估存活通路在对肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)/Apo2L细胞毒性作用敏感的Jurkat T白血病细胞反应中的参与情况。Jurkat T细胞表达TRAIL-R2/DR5和TRAIL-R4/DcR2受体,在给予TRAIL后早期(3小时)开始通过凋亡死亡,在48小时内死亡细胞百分比呈剂量依赖性增加(高达85%-90%)。细胞死亡的这种增加伴随着细胞周期G0/G1期的剂量依赖性显著(P<0.05)增加,并且用泛半胱天冬酶抑制剂z-VAD-fmk处理可使其逆转。用PI-3激酶抑制剂(LY294002)和核因子κB(NF-κB)(SN50)通路抑制剂共同处理细胞,分别以凋亡和坏死的形式导致更早且显著增加的细胞毒性。与用药理抑制剂获得的数据一致,观察到PI-3K和NF-κB的激活和核转位。总之,我们的结果提供了证据,即即使在敏感的肿瘤细胞中,TRAIL也反常地激活了促存活通路,由于这些通路的抑制导致更早且增加的细胞毒性,从而保护细胞免受TRAIL介导的死亡。